BIOMAT Database Logo BIOMAT Database Logo

The effects of topically applied hexyl nicotinate lotion on the cutaneous blood flow in patients with Raynaud's phenomenon. 1988

C B Bunker, and S Lanigan, and M H Rustin, and P M Dowd
Department of Dermatology, University College and Middlesex School of Medicine, Middlesex Hospital, London, U.K.

The effect of the epicutaneous application of 0.1% and 1.0% hexyl nicotinate lotion on upper limb skin blood flow was investigated in 25 patients with Raynaud's phenomenon (RP) and five healthy volunteers. Assessments were made using laser Doppler velocimetry. The 0.1% lotion induced an increase in cutaneous blood flow in both controls and patients when applied at different sites on the upper limb. Increased cutaneous blood flow occurred more often when the lotion was applied to the forearm than to the fingers. A greater increase in blood flow and an increased percentage of positive responses was elicited with the 1.0% hexyl nicotinate lotion. Hexyl nicotinate lotion may be of value in the topical treatment of RP.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009539 Nicotinic Acids 2-, 3-, or 4-Pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position. The 3-carboxy derivative (NIACIN) is active as a vitamin. Acids, Nicotinic
D011928 Raynaud Disease An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress. Cold Fingers, Hereditary,Raynaud Phenomenon,Raynaud's Disease,Raynauds Disease
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.

Related Publications

C B Bunker, and S Lanigan, and M H Rustin, and P M Dowd
The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon.
December 1987, The British journal of dermatology,
C B Bunker, and S Lanigan, and M H Rustin, and P M Dowd
Skin blood flow response to topically applied methyl nicotinate: Possible mechanisms.
May 2020, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI),
C B Bunker, and S Lanigan, and M H Rustin, and P M Dowd
Cutaneous pharmacokinetics of topically applied maxacalcitol ointment and lotion.
June 2008, International journal of clinical pharmacology and therapeutics,
C B Bunker, and S Lanigan, and M H Rustin, and P M Dowd
An experimentally controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud's phenomenon.
January 1979, The Journal of international medical research,
C B Bunker, and S Lanigan, and M H Rustin, and P M Dowd
Decreased oesophageal blood flow in patients with Raynaud's phenomenon.
December 1988, British journal of rheumatology,
C B Bunker, and S Lanigan, and M H Rustin, and P M Dowd
Effects of ketanserin on peripheral blood flow, haemorheology, and platelet function in patients with Raynaud's phenomenon.
January 1985, Journal of cardiovascular pharmacology,
C B Bunker, and S Lanigan, and M H Rustin, and P M Dowd
The effect of cold on blood flow in the hand of patients with Raynaud's phenomenon.
March 1973, Clinical science,
C B Bunker, and S Lanigan, and M H Rustin, and P M Dowd
The acute effects of cigarette smoking on cutaneous blood flow in smoking and non-smoking subjects with and without Raynaud's phenomenon.
April 1990, British journal of rheumatology,
C B Bunker, and S Lanigan, and M H Rustin, and P M Dowd
Premature baldness; preliminary report on treatment with topically applied estrogen lotion.
January 1953, The Journal of the Medical Society of New Jersey,
C B Bunker, and S Lanigan, and M H Rustin, and P M Dowd
Acute effect of topical minoxidil on digital blood flow in patients with Raynaud's phenomenon.
January 1995, The Journal of rheumatology,
Copied contents to your clipboard!